The negative prognostic impact of PIK3CA mutations in BC is more evident in the metastatic disease: worse median progression-free survival was observed for patients whose tumors expressed mutated versus wild-type PIK3CA, in both the control (8.6 versus 13.8 months) and pertuzumab groups (12.5 versus 21.8 months) [20]. The gene discussed is PIK3CA; the disease is breast cancer.